Importantly, in the non–EV-treated patients with mUC, NECTIN4 amplifications have no impact on OS,33 suggesting that NECTIN4 amplifications are neither indicating aggressive nor favorable tumor biology, strengthening its potential value as a pure predictive biomarker.34NECTIN4 amplification was strongly associated with EV sensitivity (BOR, 96%). This evidence concerns the gene NECTIN4 and neoplasm.